Published in Physician Law Weekly, January 17th, 2007
The BCIRG 006 study randomized patients to receive the control arm AC-T, which comprised 4 cycles of doxorubicin (A) and cyclophosphamide (C) followed by 4 cycles of Taxotere (T), or either of two experimental Herceptin (H)- and Taxotere-based therapies: AC-TH (adds 1 year of Herceptin to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly